Preferences for In-person Disclosure: Patients Declining Telephone Disclosure Characteristics and Outcomes in the Multicenter Communication Of GENetic Test Results by Telephone Study
Overview
Authors
Affiliations
Telephone disclosure of cancer genetic test results is noninferior to in-person disclosure. However, how patients who prefer in-person communication of results differ from those who agree to telephone disclosure is unclear but important when considering delivery models for genetic medicine. Patients undergoing cancer genetic testing were recruited to a multicenter, randomized, noninferiority trial (NCT01736345) comparing telephone to in-person disclosure of genetic test results. We evaluated preferences for in-person disclosure, factors associated with this preference and outcomes compared to those who agreed to randomization. Among 1178 enrolled patients, 208 (18%) declined randomization, largely given a preference for in-person disclosure. These patients were more likely to be older (P = 0.007) and to have had multigene panel testing (P < 0.001). General anxiety (P = 0.007), state anxiety (P = 0.008), depression (P = 0.011), cancer-specific distress (P = 0.021) and uncertainty (P = 0.03) were higher after pretest counseling. After disclosure of results, they also had higher general anxiety (P = 0.003), depression (P = 0.002) and cancer-specific distress (P = 0.043). While telephone disclosure is a reasonable alternative to in-person disclosure in most patients, some patients have a strong preference for in-person communication. Patient age, distress and complexity of testing are important factors to consider and requests for in-person disclosure should be honored when possible.
Rahma A, Ali B, Patrinos G, Ahmed L, Elbarazi I, Abdullahi A Hum Genomics. 2023; 17(1):63.
PMID: 37454085 PMC: 10349494. DOI: 10.1186/s40246-023-00509-0.
Dantas M, Da Silva J, Tkachenko N, Paneque M J Community Genet. 2022; 14(1):91-100.
PMID: 36414926 PMC: 9685011. DOI: 10.1007/s12687-022-00618-8.
Blondeaux E, Lambertini M, Buzzatti G, Bruzzone C, Baraga M, Pisani R J Genet Couns. 2022; 32(1):140-152.
PMID: 36036895 PMC: 10087002. DOI: 10.1002/jgc4.1630.
Costanzo S, De Summa S, Maurmo L, Digennaro M, Patruno M, Angelo Paradiso Fam Cancer. 2022; 22(1):43-48.
PMID: 35867288 PMC: 9304797. DOI: 10.1007/s10689-022-00307-y.
Binion S, Sorgen L, Peshkin B, Valdimarsdottir H, Isaacs C, Nusbaum R J Telemed Telecare. 2021; 30(2):334-343.
PMID: 34779303 PMC: 9902210. DOI: 10.1177/1357633X211052220.